Hypermarcas (OTCMKTS:HYPMY) Trading Down 7.9% - Time to Sell?

Key Points

• Hypermarcas' share price dropped 7.9%, trading at $3.84, which is significantly lower than its previous close of $4.17 and reflects a 99% decline in trading volume compared to the average.
• Scotiabank upgraded Hypermarcas to a "strong-buy" rating, contributing to the company's overall consensus rating of "Strong Buy" by analysts.
• The company reported a $0.12 EPS for the last quarter, with a market cap of $2.53 billion and a net margin of 11.28%.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s share price was down 7.9% on Monday . The stock traded as low as $3.84 and last traded at $3.84. Approximately 614 shares were traded during trading, a decline of 99% from the average daily volume of 63,580 shares. The stock had previously closed at $4.17.

Analyst Upgrades and Downgrades

Separately, Scotiabank upgraded shares of Hypermarcas to a "strong-buy" rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Strong Buy".

Hypermarcas Trading Down 4.1%

The stock has a market cap of $2.53 billion, a price-to-earnings ratio of 19.05 and a beta of 0.83. The business has a 50-day simple moving average of $4.33 and a two-hundred day simple moving average of $4.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 EPS for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.